Personalized Medicine for the Management of Benign Prostatic Hyperplasia
- 1 July 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 192 (1), 16-23
- https://doi.org/10.1016/j.juro.2014.01.114
Abstract
Purpose: Benign prostatic hyperplasia affects more than 50% of men by age 60 years, and is the cause of millions of dollars in health care expenditure for the treatment of lower urinary tract sympt...Keywords
This publication has 46 references indexed in Scilit:
- Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer SusceptibilityJournal of Urology, 2013
- Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro‐inflammatory cytokines/chemokinesEMBO Molecular Medicine, 2012
- Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH)Journal of Biological Chemistry, 2012
- Role of interleukins, IGF and stem cells in BPHDifferentiation, 2011
- The functional role of reactive stroma in benign prostatic hyperplasiaDifferentiation, 2011
- Androgens and estrogens in benign prostatic hyperplasia: Past, present and futureDifferentiation, 2011
- Characterizing Associations and SNP-Environment Interactions for GWAS-Identified Prostate Cancer Risk Markers—Results from BPC3PLOS ONE, 2011
- Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular CarcinomaGastroenterology, 2008
- A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA ConsortiumJournal of Urology, 2008
- Stromally Expressed c-Jun Regulates Proliferation of Prostate Epithelial CellsThe American Journal of Pathology, 2007